(Q33380135)

26 July 2017

1 reference

title

Alemtuzumab for B-cell chronic lymphocytic leukemia (English)

1 reference

B-cell chronic lymphocytic leukemia

26 July 2017

0 references

1 reference

1 reference

1

Tadeusz Robak

1 reference

26 July 2017

publication date

1 July 2008

1 reference

Expert Review of Anticancer Therapy

26 July 2017

published in

1 reference

26 July 2017

volume

8

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1033-1051

1 reference

The clinical and epidemiological burden of chronic lymphocytic leukaemia

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

High dose chlorambucil in the treatment of lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Monoclonal antibodies in the treatment of chronic lymphoid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Emerging information on the use of rituximab in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Novel immune-based treatment strategies for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Hematopoietic cell transplantation for chronic lymphocytic leukemia: an evolving concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

CD52 expression in hairy cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab in stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Pharmacokinetics of CAMPATH-1H: assay development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

The CD52 antigen and development of the CAMPATH antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Genomic aberrations and survival in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Recent progress in the management of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Monoclonal antibodies in the treatment of autoimmune cytopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Monoclonal antibodies: new therapeutic agents for autoimmune hemolytic anemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

The effect of treatment with Campath-1H in patients with autoimmune cytopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

The role of alemtuzumab in nonmyeloablative hematopoietic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab can successfully treat steroid-refractory acute graft-versus-host disease (aGVHD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Phase II study of alemtuzumab in chronic lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1033

10.1586/14737140.8.7.1033

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference